Safer Vectors and Strategies For Gene Therapy

更安全的基因治疗载体和策略

• 批准号: 6937591
• 负责人: GEORGE J MURPHY
• 金额: $ 4.83万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6937591
• 关键词: Safer; Vectors; Strategies; Gene; Therapy

DESCRIPTION (provided by applicant): Retroviral vectors are excellent tools for the stable delivery of gene products into cells of therapeutic interest. However, use of these vectors in a clinical setting has recently been shown to be problematic. In a gene therapy trial for the correction of Severe Combined Immune Deficiency (SCID), two patients, out of eleven, developed T-cell leukemia as a direct result of an integrated retroviral vector. In an effort to prevent undesirable outcomes in future gene therapy trials, a primary goal of this study is the development and testing of novel vectors and strategies aimed at increased safety without the loss of effectiveness. New vectors will be developed that are less likely to lead to insertional mutagenesis while still retaining the therapeutic benefits. This will require the engineering of DMA elements with enhancer-blocking activity to inhibit transactivation of adjacent genes in genomic DMA. Incorporation of a regulatable suicide gene, which could be activated in the case of an adverse outcome, will provide an additional safety feature. Lastly, the vectors and strategies discussed above along with the use of limited numbers of genetically modified cells will be tested for their ability to rescue a genetic defect in a murine model of immunodeficiency. This project is aimed at tempering efficacy with safety in producing the safest, most potent retroviral vectors for use in human gene therapy trials.

描述（由申请人提供）：逆转录病毒载体是将基因产物稳定递送至治疗目的细胞中的极好工具。然而，最近已证明这些载体在临床环境中的使用存在问题。在一项纠正严重联合免疫缺陷 (SCID) 的基因治疗试验中，11 名患者中有 2 名因整合逆转录病毒载体的直接结果而患上 T 细胞白血病。为了防止未来基因治疗试验中出现不良结果，本研究的主要目标是开发和测试新型载体和策略，旨在提高安全性而不损失有效性。将开发出不太可能导致插入突变的新载体，同时仍保留治疗效果。这需要对具有增强子阻断活性的 DMA 元件进行工程改造，以抑制基因组 DMA 中相邻基因的反式激活。纳入可调节的自杀基因（在出现不良结果的情况下可以被激活）将提供额外的安全功能。最后，将测试上述载体和策略以及使用有限数量的转基因细胞在免疫缺陷小鼠模型中挽救遗传缺陷的能力。该项目旨在提高功效和安全性，生产用于人类基因治疗试验的最安全、最有效的逆转录病毒载体。